Karyopharm staffing up in MA; How often do biobucks come through?;

@FierceBiotech:  Gilead's 'open to suggestion' on its next big M&A splash. Articles | Follow @FierceBiotech

@JohnCFierce: T-Vec panel demonstrates just how accepting the FDA and its panels are when it comes to "meh" cancer drugs. | Follow @JohnCFierce

@DamianFierce: Shouts to the 19 $OPHT workers who won $58M on the New York lottery. Article | Follow @DamianFierce

> Karyopharm Therapeutics ($KPTI) is planning to hire about 50 people throughout the year as it presses forward with a stable of cancer candidates. Story

> Isis ($ISIS) pocketed another $10 million milestone payment in its wide-ranging collaboration with Biogen ($BIIB). More

> Atlas Venture's Bruce Booth takes a look at how often those backloaded biotech deals actually pay out their promised milestones. Post

Medical Device News

@FierceMedDev: Medtronic to test renal denervation as treatment for atrial fibrillation. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Kaiser backs startup in $12.5M round to speed healthcare data integration. News | Follow @VarunSaxena2

@EmilyWFierce: Abbott grabs #FDA OK for early pregnancy blood test. FierceDiagnostics Story | Follow @EmilyWFierce

> Greatbatch spins off neurostimulation unit to speed up growth. Article.

> Ninox gets $10M Series B to get wearable sleep apnea device through regulators. More

Pharma News

@FiercePharma: From the pharma C-suite: Notable, quotable remarks on Asia, emerging markets for Q1. Story | Follow @FiercePharma

@EricPFierce: Drug shortages become way for #Mylan to parry against #Teva but will the FTC care? More | Follow @EricPFierce

@CarlyHFierce: #ICYMI yesterday: Teva CEO 'takes the high road' to rebut Mylan chairman's attack. News | Follow @CarlyHFierce

> Small group of branded drugs like Nexium, Copaxone make up huge part of Medicare spend. Article

> Novartis faces more kickback scrutiny after $45M Express Scripts settlement. Story

Suggested Articles

Q32 Bio raised $60 million to push its lead antibody through the clinic and bolster its pipeline and the technology behind it.

Sanofi is teaming up with Merck while AstraZeneca taps Arcus as the future of cancer work is very much made together.

The action follows the FDA’s decision to reject a filing for approval of the JAK1 inhibitor in rheumatoid arthritis due to toxicity concerns.